NCT03646461: An ongoing trial by University of California, San Diego
This trial is ongoing. It must report results 9 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03646461 |
|---|---|
| Title | A Multi-Institutional, Open-Label, Randomized, Phase II Trial Of Ibrutinib In Combination With EGFR Inhibition Or PD-1 Inhibition In Patients With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 17, 2018 |
| Completion date | Jan. 11, 2025 |
| Required reporting date | Jan. 11, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |